DexCom Inc. closed 23.71% short of its 52-week high of $89.98, which the company reached on July 30th. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 12 High Quality Stocks to Buy for the Long Term. On June 15, 2026, Piper Sandler ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

DexCom, Inc. (DXCM Quick Quote DXCM - Free Report) reported first-quarter 2025 adjusted earnings per share (EPS) of 32 cents, which missed the Zacks Consensus Estimate of 33 cents by 3%. The company ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...

DexCom DXCM recently announced that it will begin rolling out its fully reimagined Stelo app experience in the United States ...

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...